JP2019518052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518052A5 JP2019518052A5 JP2018565750A JP2018565750A JP2019518052A5 JP 2019518052 A5 JP2019518052 A5 JP 2019518052A5 JP 2018565750 A JP2018565750 A JP 2018565750A JP 2018565750 A JP2018565750 A JP 2018565750A JP 2019518052 A5 JP2019518052 A5 JP 2019518052A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- tumor
- treatment
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610428049 | 2016-06-16 | ||
| CN201610428049.6 | 2016-06-16 | ||
| CN201610674021.0 | 2016-08-15 | ||
| CN201610674021 | 2016-08-15 | ||
| PCT/CN2017/088030 WO2017215588A1 (zh) | 2016-06-16 | 2017-06-13 | 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518052A JP2019518052A (ja) | 2019-06-27 |
| JP2019518052A5 true JP2019518052A5 (enExample) | 2020-05-14 |
| JP6900406B2 JP6900406B2 (ja) | 2021-07-07 |
Family
ID=60663995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565750A Active JP6900406B2 (ja) | 2016-06-16 | 2017-06-13 | Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10654868B2 (enExample) |
| EP (1) | EP3473628B1 (enExample) |
| JP (1) | JP6900406B2 (enExample) |
| KR (1) | KR102351270B1 (enExample) |
| CN (1) | CN109311908B (enExample) |
| WO (1) | WO2017215588A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11261196B2 (en) | 2017-12-13 | 2022-03-01 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Salt serving as AKT inhibitor and crystal thereof |
| WO2022121788A1 (zh) * | 2020-12-07 | 2022-06-16 | 南京正大天晴制药有限公司 | 一种吡唑并氮杂卓类akt抑制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887864B2 (en) * | 2002-03-12 | 2005-05-03 | Hoffmann-La Roche Inc. | Azepane derivatives |
| CN101094833A (zh) * | 2004-07-12 | 2007-12-26 | 伊邓药品公司 | 四肽类似物 |
| US8207180B2 (en) * | 2006-11-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | Tricyclic indoles and (4,5-dihydro) indoles |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| DE602008003055D1 (de) * | 2007-05-31 | 2010-12-02 | Nerviano Medical Sciences Srl | Zyklokondensierte Azaindole, die als Kinase-Hemmer wirken |
| EP2240029A4 (en) | 2008-01-07 | 2012-08-22 | Synta Pharmaceuticals Corp | COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES |
| JP2011525928A (ja) | 2008-06-26 | 2011-09-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ａｋｔ活性の阻害剤 |
| WO2012065935A1 (en) | 2010-11-17 | 2012-05-24 | F. Hoffmann-La Roche Ag | Methods of treating tumors |
-
2017
- 2017-06-13 JP JP2018565750A patent/JP6900406B2/ja active Active
- 2017-06-13 EP EP17812699.1A patent/EP3473628B1/en active Active
- 2017-06-13 WO PCT/CN2017/088030 patent/WO2017215588A1/zh not_active Ceased
- 2017-06-13 US US16/309,648 patent/US10654868B2/en active Active
- 2017-06-13 KR KR1020197001396A patent/KR102351270B1/ko active Active
- 2017-06-13 CN CN201780037686.3A patent/CN109311908B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20260007I1 (fi) | Vimseltinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
| JP2016518337A5 (enExample) | ||
| JP2015147774A5 (enExample) | ||
| JP2017509667A5 (enExample) | ||
| JP2016515522A5 (enExample) | ||
| EP3835296A4 (en) | KETOAMIDE COMPOUND AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| WO2016131067A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| JP2019526543A5 (enExample) | ||
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| JP2018202656A5 (enExample) | ||
| JP2016535100A5 (enExample) | ||
| JP2020536085A5 (enExample) | ||
| JP2009536652A5 (enExample) | ||
| WO2017062468A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| SG11202105540YA (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| EP3597208A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ATPIF1 FOR THE TREATMENT OF DIABETES | |
| JP2016540030A5 (enExample) | ||
| JP2017537912A5 (enExample) | ||
| CY1123844T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| JP2022536655A5 (enExample) | ||
| JP2017197541A5 (enExample) | ||
| HUE053472T2 (hu) | Gyengén oldódó komplex vagy szolvátja, gyógyászati készítmény és alkalmazása |